A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease
Latest Information Update: 05 Nov 2021
At a glance
- Drugs NPT 088 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Proclara Biosciences
- 14 Aug 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 According to a Proclara Biosciences media release, Enrollment Completed in this trial and Topline Data Expected 1Q of 2019
- 17 Jul 2018 Status changed from recruiting to active, no longer recruiting.